Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Mortality among patients with chronic kidney disease (CKD) is largely a consequence of
cardiovascular disease (CVD) and is a particular concern given the increasing prevalence of …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect
the kidneys and heart, but the underlying mechanism remains poorly understood …

Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that
ultimately develops into end-stage kidney disease (ESKD) when not managed …

Aims This study aims to examine the effectiveness of using sodium glucose transporter-2
inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients …

Recent studies have demonstrated that dapagliflozin, a sodium-glucose cotransporter type 2
(SGLT2) inhibitor, prevents endothelial dysfunction; however, direct effects of dapagliflozin …

The sodium–glucose cotransporter 2 (SGLT2) mainly carries out glucose reabsorption in the
kidney. Familial renal glycosuria, which is a mutation of SGLT2, is known to excrete glucose …

Background Chronic kidney disease (CKD) poses a significant health risk in contemporary
society. Current CKD treatments primarily involve renin-angiotensin-aldosterone system …

The current nomenclature for cardiorenal syndrome is problematic owing to its chronological
approach and the systemic nature of some of the subtypes. We suggest adoption of a new …